Switching tumor-derived extracellular vesicles off and on via targeted proteolysis to shift toward immunogenic phenotypes
{{output}}
Despite compelling evidence that tumor-derived extracellular vesicles (TEVs) exhibit either pro- or antitumorigenic phenotypes, pharmacological efforts have focused primarily on their indiscriminate suppression. Here, we propose a strategy of "switching TEVs ... ...
